Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Atrial Fibrillation in CLL/SLL Patients on Ibrutinib

Mohammed Farooqui, DO, Janet Valdez, PA-C, Susan Soto, RN, Amanda Bray, RN, Xin Tian, PhD, Adrian Wiestner, MD PhD

Blood (2015) 126 (23): 2933.

https://doi.org/10.1182/blood.V126.23.2933.2933

Published: 2015

Journal Articles

Single Agent Ibrutinib in CLL/SLL Patients with and without Deletion 17p

Mohammed Farooqui, DO, Janet Valdez, PA-C, Susan Soto, RN, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Francine Thomas, BS, Xin Tian, PhD, Irina Maric, Adrian Wiestner, MD PhD

Blood (2015) 126 (23): 2937.

https://doi.org/10.1182/blood.V126.23.2937.2937

Published: 2015

Journal Articles

Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia Accelerates Count Recovery and Increases Response Rates

Danielle M. Townsley, MD, Bogdan Dumitriu, MD, Phillip Scheinberg, MD, Ronan Desmond, MD, FRCPath, Xingmin Feng, PhD, Olga Rios, RN, Barbara Weinstein, RN, Janet Valdez, PA-C, Thomas Winkler, MD, Marie Desierto, BS, Harshraj Leuva, MBBS, Colin Wu, PhD, Katherine R. Calvo, MD, PhD, Andre Larochelle, MD, PhD, Cynthia E. Dunbar, MD, Neal S. Young, MD

Blood (2015) 126 (23): LBA-2.

https://doi.org/10.1182/blood.V126.23.LBA-2.LBA-2

Published: 2015

Journal Articles

In Patients With Chronic Lymphocytic Leukemia (CLL) Ibrutinib Effectively Reduces Clonal IgM Paraproteins and Serum Free Light Chains While Increasing Normal IgM, IgA Serum Levels, Suggesting a Nascent Recovery Of Humoral Immunity

Georg Aue, MD, Mohammed Farooqui, DO, Jade Jones, Janet Valdez, PA, Sabrina E. Martyr, MD, Susan Soto, RN, Maryalice Stetler-Stevenson, MD, PhD, Constance Yuan, MD, PhD, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 4182.

https://doi.org/10.1182/blood.V122.21.4182.4182

Published: 2013

Journal Articles

Effective Inhibition Of Tumor Microenvironment Interactions In CLL Patients Treated With The BTK Inhibitor Ibrutinib Results In Sustained Inhibition Of Tumor Proliferation and Survival Pathways

Sarah E. M. Herman, PhD, Rashida Z Mustafa, BS, Sabrina E. Martyr, MD, Jennifer Gyamfi, MS, Janet Valdez, PA, Susan Soto, RN, Mohammed Farooqui, DO, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 118.

https://doi.org/10.1182/blood.V122.21.118.118

Published: 2013

Journal Articles

Single Agent Ibrutinib (PCI-32765) Achieves Equally Good and Durable Responses In Chronic Lymphocytic Leukemia (CLL) Patients With and Without Deletion 17p

Mohammed Farooqui, DO, Georg Aue, MD, Janet Valdez, PA, Sabrina Martyr, MD, Jade Jones, Susan Soto, RN, Maryalice Stetler-Stevenson, MD, PhD, Constance Yuan, MD, PhD, Diane C Arthur, M.D., Francine Thomas, B.S., Xin Tian, PhD, Delong Liu, PhD, Irina Maric, MD, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 673.

https://doi.org/10.1182/blood.V122.21.673.673

Published: 2013

Journal Articles

Direct in Vivo Evidence of Increased Chronic Lymphocytic Leukemia Cell Proliferation in Lymph Nodes Compared to Bone Marrow and Peripheral Blood

Thomas M. Herndon, MD, Shih-Shih Chen, Ph.D., Michelle Gatmaitan, Claire Emson, PhD, Janet Valdez, PA, Nakhle Saba, MD, Nicholas Chiorazzi, MD, Adrian Wiestner, MD, PhD

Blood (2012) 120 (21): 184.

https://doi.org/10.1182/blood.V120.21.184.184

Published: 2012

Journal Articles

Phase I Study of On 01910.Na (rigosertib), a Multikinase PI3K Inhibitor in Relapsed/Refractory B-Cell Malignancies

Mark Roschewski, MD, Mohammed Farooqui, DO, Georg Aue, MD, Clifton C. Mo, MD, Janet Valdez, PA, Susan Soto, RN, Patricia Perez-Galan, PhD, Francois Wilhelm, MD, PhD., Adrian Wiestner, MD, PhD

Blood (2012) 120 (21): 1803.

https://doi.org/10.1182/blood.V120.21.1803.1803

Published: 2012

Journal Articles

Ibrutinib (PCI 32765) Rapidly Improves Platelet Counts in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) Patients and Has Minimal Effects On Platelet Aggregation

Mohammed Farooqui, DO, Jay Nelson Lozier, Janet Valdez, PA, Nakhle Saba, MD, Ajunae Wells, Susan Soto, RN, Delong Liu, Ph.D., Georg Aue, MD, Adrian Wiestner, MD, PhD

Blood (2012) 120 (21): 1789.

https://doi.org/10.1182/blood.V120.21.1789.1789

Published: 2012

Journal Articles

Rapid Decrease in Overall Tumor Burden On Ibrutinib (PCI-32765) in CLL Despite Transient Increase in ALC Indicates a Significant Degree of Treatment Induced Cell Death.

Mohammed Farooqui, DO, Georg Aue, MD, Janet Valdez, PA, Nakhle Saba, MD, Sarah E. M. Herman, PhD, Andrew Lipsky, MS IV, Leodayan Bojanowski, DNP, CIP, RN, Ajunae Wells, Susan Soto, RN, Delong Liu, Ph.D., Adrian Wiestner, MD, PhD

Blood (2012) 120 (21): 2899.

https://doi.org/10.1182/blood.V120.21.2899.2899

Published: 2012

Journal Articles

Correlates of Lenalidomide Induced Immune Stimulation and Response in CLL: Analysis in Patients on Treatment

Georg Aue, M.D., Stefania Pittaluga, MD, Delong Liu, Ph.D., Larry Stennett, Susan Soto, RN, Janet Valdez, PA, Angelique Biancotto, PhD, J. Philip McCoy, Jr., PhD, Adrian Wiestner, MD, PhD

Blood (2011) 118 (21): 979.

https://doi.org/10.1182/blood.V118.21.979.979

Published: 2011

Journal Articles

Phase II Trial of Pulse Dosed Lenalidomide In Previously Treated Chronic Lymphocytic Leukemia

Georg Aue, M.D., Susan Soto, RN, Janet Valdez, PA, Diane C Arthur, M.D., Xin Tian, Adrian Wiestner, M.D., Ph.D.

Blood (2010) 116 (21): 1383.

https://doi.org/10.1182/blood.V116.21.1383.1383

Published: 2010

Journal Articles

A Phase II Trial of Pulse Dosing Lenalidomide: 3 Weeks On 3 Weeks off in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Georg Aue, MD, Susan Soto, RN, Janet Valdez, PA, Diane C. Arthur, MD, Mark Roschewski, MD, Adrian Wiestner, MD, PhD

Blood (2009) 114 (22): 3427.

https://doi.org/10.1182/blood.V114.22.3427.3427

Published: 2009

Journal Articles

Lenalidomide Induced Cytokine Release Syndrome in Chronic Lymphocytic Leukemia (CLL): Clinical and Laboratory Correlates of Immune Activation.

Georg Aue, MD, Ndegwa Njuguna, MD, Xin Tian, PhD, Janet Valdez, PA, Susan Soto, RN, J. Philip McCoy, Jr., PhD, Leigh Samsel, Berengere Vire, PhD, Keyvan Keyvanfar, Stefania Pittaluga, MD, Adrian Wiestner, MD, PhD

Blood (2008) 112 (11): 2099.

https://doi.org/10.1182/blood.V112.11.2099.2099

Published: 2008

NARROW

Atrial Fibrillation in CLL/SLL Patients on Ibrutinib

Single Agent Ibrutinib in CLL/SLL Patients with and without Deletion 17p

Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia Accelerates Count Recovery and Increases Response Rates

In Patients With Chronic Lymphocytic Leukemia (CLL) Ibrutinib Effectively Reduces Clonal IgM Paraproteins and Serum Free Light Chains While Increasing Normal IgM, IgA Serum Levels, Suggesting a Nascent Recovery Of Humoral Immunity

Effective Inhibition Of Tumor Microenvironment Interactions In CLL Patients Treated With The BTK Inhibitor Ibrutinib Results In Sustained Inhibition Of Tumor Proliferation and Survival Pathways

Single Agent Ibrutinib (PCI-32765) Achieves Equally Good and Durable Responses In Chronic Lymphocytic Leukemia (CLL) Patients With and Without Deletion 17p

Direct in Vivo Evidence of Increased Chronic Lymphocytic Leukemia Cell Proliferation in Lymph Nodes Compared to Bone Marrow and Peripheral Blood

Phase I Study of On 01910.Na (rigosertib), a Multikinase PI3K Inhibitor in Relapsed/Refractory B-Cell Malignancies

Ibrutinib (PCI 32765) Rapidly Improves Platelet Counts in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) Patients and Has Minimal Effects On Platelet Aggregation

Rapid Decrease in Overall Tumor Burden On Ibrutinib (PCI-32765) in CLL Despite Transient Increase in ALC Indicates a Significant Degree of Treatment Induced Cell Death.

Correlates of Lenalidomide Induced Immune Stimulation and Response in CLL: Analysis in Patients on Treatment

Phase II Trial of Pulse Dosed Lenalidomide In Previously Treated Chronic Lymphocytic Leukemia

A Phase II Trial of Pulse Dosing Lenalidomide: 3 Weeks On 3 Weeks off in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Lenalidomide Induced Cytokine Release Syndrome in Chronic Lymphocytic Leukemia (CLL): Clinical and Laboratory Correlates of Immune Activation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only